Theratechnologies to Announce Second Quarter Financial Results
MONTREAL – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a company committed to advancing biopharmaceutical innovations, is set to report its financial results for the second quarter of 2025. This financial period, which concluded on May 31, will be reviewed on July 9, 2025.
Highlights Ahead of the Announcement
Following a recent announcement regarding significant developments within the Company, a conference call is not planned for this report. Investors are encouraged to closely follow the results to better understand the ongoing trajectory of Theratechnologies.
About Theratechnologies
Theratechnologies is recognized as a specialty biopharmaceutical firm dedicated to the commercialization of innovative therapies. Their goal is to shift the standards of medical care through advances in biopharmaceutical solutions. The Company focuses on developing therapies that address pressing health challenges, paving the way for improved patient outcomes.
What Makes Theratechnologies Stand Out?
Theratechnologies has carved a niche in the biopharmaceutical industry through its commitment to research and development. Their innovative therapies target unmet medical needs, which is critical in an industry that is constantly evolving. This commitment is reflected in their robust pipeline, which promises to deliver transformative options for patients.
Innovative Therapies
The portfolio of Theratechnologies showcases cutting-edge therapies that not only aim to improve quality of life but also work towards redefining treatment standards for various conditions. This focus on innovative approaches attracts both investors and healthcare professionals, emphasizing the potential for significant impact.
Investing in Theratechnologies
As a publicly traded entity on both the TSX and NASDAQ, Theratechnologies offers investors a chance to be part of a revolution in the biopharmaceutical space. The Company’s performance and strategic decisions make it a compelling option for those looking to invest in the health sector. Through regular updates and financial disclosures, investors can monitor the Company’s growth and adjust their strategies accordingly.
Future Expectations
Looking forward, Theratechnologies is positioned for continued growth and innovation. The upcoming financial results will provide valuable insights into the Company’s performance and future direction. Stakeholders can anticipate an informative release that outlines key developments and strategic initiatives.
Investor and Media Contacts
For additional inquiries, investors and the media are encouraged to reach out. Investor inquiries can be directed to Philippe Dubuc, Senior Vice President and Chief Financial Officer, who is available at pdubuc@theratech.com or by phone at 1-438-315-6608.
Media inquiries should be directed to Julie Schneiderman, Senior Director of Communications & Corporate Affairs, at communications@theratech.com or by calling 1-514-336-7800.
Frequently Asked Questions
What is Theratechnologies' main focus?
Theratechnologies aims to commercialize innovative therapies that redefine treatment standards within the biopharmaceutical industry.
When will the second quarter financial results be announced?
The Company plans to report its Q2 2025 financial results on July 9, 2025.
Is a conference call scheduled for the financial report?
No, there will not be a conference call following the financial results announcement due to recent developments within the Company.
How can I learn more about Theratechnologies' innovations?
For detailed information, please visit the Company's official website or their profiles on leading financial platforms.
Who can I contact for investor inquiries?
Investor inquiries can be directed to Philippe Dubuc, Senior Vice President and CFO, at pdubuc@theratech.com.
